Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

Journal of Neuro-Oncology

Volumn 95, Issue 3, 2009, Pages 393-400

  Quinn, Jennifer A ^a   Jiang, Sara Xiaoyin ^a   Reardon, David A ^a   Desjardins, Annick ^a   Vredenburgh, James J ^a   Friedman, Allan H ^a   Sampson, John H ^a   McLendon, Roger E ^b   Herndon II, James E ^b   Friedman, Henry S ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Glioblastoma multiforme; Irinotecan; Newly diagnosed; Radiotherapy; Temozolomide

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBAMAZEPINE; FOSPHENYTOIN SODIUM; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TEMOZOLOMIDE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD TOXICITY; BRAIN HEMORRHAGE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LUNG DISEASE; LUNG INFECTION; LUNG INFILTRATE; MALE; MULTIPLE CYCLE TREATMENT; NEUROSURGERY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROTEIN EXPRESSION; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TYPHLITIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70450237808     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9937-x     Document Type: Article

References (30)

1. 6- benzylguanine in adults with recurrent malignant glioma: New approaches to Brain Tumor Therapy CNS Consortium trial J Clin Oncol 25 399 404 10.1200/JCO.2006.06. 6290 10.1200/JCO.2006.06.6290 17264335 (Pubitemid 350002988)
2. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 10.1056/NEJMoa043330 10.1056/NEJMoa043330 15758009 (Pubitemid 40349501)
3. WK Yung RE Albright J Olson R Fredericks K Fink MD Prados M Brada A Spence RJ Hohl W Shapiro M Glantz H Greenberg RG Selker NA Vick R Rampling H Friedman P Phillips J Bruner N Yue D Osoba S Zaknoen VA Levin 2000 A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse Br J Cancer 83 588 593 10.1054/bjoc.2000.1316 10.1054/bjoc.2000.1316 10944597 (Pubitemid 30636298)
4. WK Yung MD Prados R Yaya-Tur SS Rosenfeld M Brada HS Friedman R Albright J Olson SM Chang AM O'Neill AH Friedman J Bruner N Yue M Dugan S Zaknoen VA Levin 1999 Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group J Clin Oncol 17 2762 2771 10561351
5. TT Batchelor MR Gilbert JG Supko KA Carson LB Nabors SA Grossman GJ Lesser T Mikkelsen S Phuphanich NCNSC 2004 Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11 Neuro-oncology 6 21 27 10.1215/S1152851703000218 10.1215/S1152851703000218 14769136 (Pubitemid 38139635)
6. TF Cloughesy E Filka J Kuhn G Nelson F Kabbinavar H Friedman LL Miller GL Elfring 2003 Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen Cancer 97 2381 2386 10.1002/cncr.11306 10.1002/cncr.11306 12712460
7. HS Friedman WP Petros AH Friedman LJ Schaaf T Kerby J Lawyer M Parry PJ Houghton S Lovell K Rasheed T Cloughsey ES Stewart OM Colvin JM Provenzale RE McLendon DD Bigner I Cokgor M Haglund J Rich D Ashley J Malczyn GL Elfring LL Miller 1999 Irinotecan therapy in adults with recurrent or progressive malignant glioma J Clin Oncol 17 1516 1525 10334539
8. E Raymond M Fabbro V Boige O Rixe M Frenay G Vassal S Faivre E Sicard C Germa JM Rodier L Vernillet JP Armand 2003 Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma Ann Oncol 14 603 614 10.1093/annonc/mdg159 10.1093/annonc/mdg159 12649109 (Pubitemid 41295091)
9. CD Turner S Gururangan J Eastwood K Bottom M Watral R Beason RE McLendon AH Friedman S Tourt-Uhlig LL Miller HS Friedman 2002 Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience Neuro-oncology 4 102 108 10.1215/15228517-4-2-102 10.1215/15228517-4-2-102 11916501
10. MR Gilbert JG Supko T Batchelor G Lesser JD Fisher S Piantadosi S Grossman 2003 Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma Clin Cancer Res 9 2940 2949 12912940
11. MD Prados WK Yung KA Jaeckle HI Robins MP Mehta HA Fine PY Wen TF Cloughesy SM Chang MK Nicholas D Schiff HS Greenberg L Junck KL Fink KR Hess J Kuhn 2004 Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study Neuro-oncology 6 44 54 10.1215/S1152851703000292 10.1215/S1152851703000292 14769140 (Pubitemid 38139639)
12. ES Newlands GR Blackledge JA Slack GJ Rustin DB Smith NS Stuart CP Quarterman R Hoffman MF Stevens MH Brampton, et al. 1992 Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) Br J Cancer 65 287 291 1739631
13. 6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models Clin Cancer Res 6 4110 4118 11051264
14. VJ Patel GB Elion PJ Houghton S Keir AE Pegg SP Johnson ME Dolan DD Bigner HS Friedman 2000 Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft Clin Cancer Res 6 4154 4157 11051270
15. 6-methylguanine Cancer Res 61 53 58 11196197
16. DA Reardon JA Quinn JN Rich A Desjardins J Vredenburgh S Gururangan S Sathornsumetee M Badruddoja R McLendon J Provenzale JE Herndon II JM Dowell JL Burkart HB Newton AH Friedman HS Friedman 2005 Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma Cancer 104 1478 1486 10.1002/cncr.21316 10.1002/cncr.21316 16088964 (Pubitemid 41356163)
17. ME Loghin MD Prados P Wen L Junck F Lieberman H Fine KL Fink M Metha J Kuhn K Lamborn SM Chang T Cloughesy LM DeAngelis IH Robins KD Aldape WK Yung 2007 Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium study Clin Cancer Res 13 7133 7138 10.1158/1078-0432.CCR-07-0874 10.1158/1078-0432.CCR-07-0874 18056194 (Pubitemid 350276899)
18. DR Macdonald TL Cascino SC Schold Jr JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 2358840
19. 6- methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas Lab Investig 78 643 644 9605190
20. MR Gilbert HS Friedman JF Kuttesch MD Prados JJ Olson GH Reaman SL Zaknoen 2002 A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy Neuro-oncology 4 261 267 10.1215/15228517-4-4-261 10.1215/15228517-4-4-261 12356356
21. E Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 29 41 10.2307/2281868 10.2307/2281868
22. M Brada S Ashley A Dowe A Gonsalves A Huchet G Pesce M Reni F Saran B Wharram M Wilkins P Wilkins 2005 Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide Ann Oncol 16 942 949 10.1093/annonc/mdi183 10.1093/annonc/mdi183 15870090 (Pubitemid 40903921)
23. 6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma J Clin Oncol 16 3851 3857 9850030
24. R Stupp PY Dietrich S Ostermann Kraljevic A Pica I Maillard P Maeder R Meuli R Janzer G Pizzolato R Miralbell F Porchet L Regli N de Tribolet RO Mirimanoff S Leyvraz 2002 Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20 1375 1382 10.1200/JCO.20.5. 1375 10.1200/JCO.20.5.1375 11870182 (Pubitemid 34177445)
25. ME Hegi A-C Diserens T Gorlia M-F Hamou N de Tribolet M Weller JM Kros JA Hainfellner W Mason L Mariani JEC Bromberg P Hau RO Mirimanoff JG Cairncross RC Janzer R Stupp 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 10.1056/NEJMoa043331 10.1056/NEJMoa043331 15758010 (Pubitemid 40349502)
26. 6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 88 1004 1011 10.1038/sj.bjc. 6600827 10.1038/sj.bjc.6600827 12671695 (Pubitemid 36560766)
27. MF Paz R Yaya-Tur I Rojas-Marcos G Reynes M Pollan L Aguirre-Cruz JL Garcia-Lopez J Piquer MJ Safont C Balana M Sanchez-Cespedes M Garcia-Villanueva L Arribas M Esteller 2004 CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas Clin Cancer Res 10 4933 4938 10.1158/1078-0432.CCR-04-0392 10.1158/1078-0432.CCR-04- 0392 15297393 (Pubitemid 39099766)
28. 6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide J Clin Oncol 25 1470 1475 10.1200/JCO.2006.07.4807 10.1200/JCO.2006.07.4807 17442989 (Pubitemid 46733073)
29. AA Brandes A Tosoni G Cavallo R Bertorelle V Gioia E Franceschi M Biscuola V Blatt L Crino M Ermani 2006 Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) Br J Cancer 95 1155 1160 10.1038/sj.bjc.6603376 10.1038/sj.bjc.6603376 17024124 (Pubitemid 44658477)
30. 6-benzylguanine (O6-BG) in adults with recurrent malignant glioma. Cancer (in press)